title: Cutaneous larva migrans in travelers: synopsis of histories, symptoms, and treatment of 98 patients.
abstract: The symptoms, medical history, and treatment of 98 patients with cutaneous larva migrans (creeping eruption) who attended a travel-related-disease clinic during a period of 4 years are reviewed. This condition is caused by skin-penetrating larvae of nematodes, mainly of the hookworm Ancylostoma braziliense and other nematodes of the family Ancylostomidae. Despite the ubiquitous distribution of these nematodes, in the investigated group only travelers to tropical and subtropical countries were affected; 28.9% of the patients had symptoms for > 1 month, and for 24.5% the probable incubation period was > 2 weeks. The efflorescences typically were on the lower extremities (73.4% of all locations). The buttocks and anogenital region were affected in 12.6% of all locations, and the trunk and upper extremities each were affected in 7.1%. Only a minority of patients presented with eosinophilia or an elevated serum level of IgE. No other laboratory data appeared to be related to the disease. Therapy with topical thiabendazole was successful for 98% of the patients. Systemic antihelmintic therapy was necessary in two cases because of disseminated, extensive infection.
authors.affiliation: Department of Infectious Diseases and Tropical Medicine, University Hospital, University of Munich, Germany.
authors.forename: T
authors.initials: T
authors.lastname: Jelinek
authors.forename: H
authors.initials: H
authors.lastname: Maiwald
authors.forename: H D
authors.initials: HD
authors.lastname: Nothdurft
authors.forename: T
authors.initials: T
authors.lastname: Löscher
mesh_terms: D000328:Adult; D000349:Africa / Q000453:epidemiology; D000569:Americas / Q000453:epidemiology; D001208:Asia / Q000453:epidemiology; D005260:Female; D005858:Germany / Q000453:epidemiology; D006801:Humans; D007815:Larva Migrans / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology*; D008297:Male; D012867:Skin / Q000469:parasitology* / Q000473:pathology; D013827:Thiabendazole / Q000008:administration & dosage / Q000627:therapeutic use; D014195:Travel
chemical_list: D013827:Thiabendazole